贝伐珠单抗联合卡铂及多西他赛治疗对复发性卵巢癌血清相关因子和预后的影响

Effect of bevacizumab combined with carboplatin and docetaxel on serum-related factors and prognosis in recurrent ovarian cancer

目的探讨贝伐珠单抗联合卡铂及多西他赛治疗对复发性卵巢癌血清相关因子和预后的影响。方法选取2022年1月1日~2023年6月30日收治的32例复发性卵巢癌患者作为研究对象,采用简单随机分组法,分为研究组(n=16)和对照组(n=16)。对照组采取卡铂、多西他赛治疗,研究组采取贝伐珠单抗、卡铂、多西他赛联合治疗。比较两组治疗前、治疗6个疗程后的肿瘤标志物[糖类抗原125(CA125)、人附睾蛋白4(HE4)]、血管内皮生长因子(VEGF),比较两组的不良反应与近期疗效。结果治疗后,两组的CA125、HE4水平较治疗前下降(P<0.05);研究组的CA125、HE4水平低于对照组(P<0.05)。治疗后,两组的VEGF水平较治疗前下降(P<0.05);研究组的VEGF水平低于对照组(P<0.05)。治疗6个疗程内,研究组不良反应总发生率为62.50%,对照组为50.00%,差异无统计学意义(P>0.05)。治疗6个疗程后RR、DCR比较,研究组显著高于对照组(P<0.05)。结论贝伐珠单抗联合卡铂、多西他赛治疗复发性卵巢癌,能改善肿瘤标志物及血管生长因子水平,提高抗肿瘤效果,疗效显著且安全性较高。

Objective To investigate the effect of bevacizumab combined with carboplatin and docetaxel on the serum related factors and prognosis of recurrent ovarian cancer.Methods A total of 32 patients with recurrent ovarian cancer admitted from 2022.1.1 to 2023.6.30 were selected as the study subjects,and they were divided into the study group(n=16)and the control group(n=16)by simple random grouping method.The control group was treated with carboplatin and docetaxel,and the study group was treated with a combination of bevacizumab,carboplatin and docetaxel.The tumor markers[carbohydrate antigen 125(CA125),human epididymal protein 4(HE4)]and vascular endothelial growth factor(VEGF)before and after 6 courses of treatment were compared between the two groups,and the adverse reactions and short-term efficacy of the two groups were compared.Results After treatment,the CA125 and HE4 levels in the two groups decreased compared with those before treatment(P<0.05).After treatment,the CA125 and HE4 levels in the study group were lower than those in the control group(P<0.05).After treatment,the VEGF in the two groups decreased compared with that before treatment(P<0.05),and after treatment,the VEGF in the study group was lower than that in the control group(P<0.05).The total incidence of adverse reactions in the study group was 62.50%compared with that in the control group(50.00%)after 6 courses of treatment,and the difference was not statistically significant(P>0.05).After 6 courses of treatment,the RR and DCR of the study group were significantly higher than those of the control group(P<0.05).Conclusion Bevacizumab combined with carboplatin and docetaxel in the treatment of recurrent ovarian cancer can improve the levels of tumor markers and vascular growth factor,and improve the anti-tumor effect,with significant efficacy and high safety.